Premium
PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC cIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA
Author(s) -
Samaniego F.,
Hollebecque A.,
Foss F.,
Lister J.,
Mita M.,
WagnerJohnston N.,
Dyer M.,
You B.,
Prica A.,
HernandezLlizaliturri F.,
Ferraldeschi R.,
Chan D.,
Zhang J.,
Mehta A.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.211_2631
Subject(s) - medicine , lymphoma , mycosis fungoides , refractory (planetary science) , adverse effect , peripheral t cell lymphoma , brentuximab vedotin , oncology , cutaneous t cell lymphoma , clinical endpoint , phases of clinical research , gastroenterology , t cell , chemotherapy , clinical trial , immunology , hodgkin lymphoma , immune system , physics , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom